Genetic variant rs10251977 (G>A) in EGFR-AS1 modulates the expression of EGFR isoforms A and D

Genetic variant rs10251977 (G>A) in EGFR-AS1 modulates the expression of EGFR isoforms A and D

Abstract Tyrosine kinase inhibitor is an effective chemo-therapeutic drug against tumors with deregulated EGFR pathway. Recently, a genetic variant rs10251977 (G>A) in exon 20 of EGFR reported to act as a prognostic marker for HNSCC. Genotyping of this polymorphism in oral cancer patients showed...

Full description

Bibliographic Details
Main Authors:	Shankar Dhamodharan, Mathew Maria Rose, Sundaram Reddy Chakkarappan, Karuppiah Vijayamuthuramalingam Umadharshini, Ramalingam Arulmurugan, Shanmugam Subbiah, Ituro Inoue, Arasambattu Kannan Munirajan
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-04-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-88161-3

Similar Items

EGFR soluble isoforms and their transcripts are expressed in meningiomas.
by: Angélique Guillaudeau, et al.
Published: (2012-01-01)

LncRNA OIP5-AS1 is overexpressed in undifferentiated oral tumors and integrated analysis identifies as a downstream effector of stemness-associated transcription factors
by: Ganesan Arunkumar, et al.
Published: (2018-05-01)

EGFR isoforms and gene regulation in human endometrial cancer cells
by: Maihle Nita J, et al.
Published: (2010-06-01)

The molecular mechanisms of D-Cbl isoforms in regulation of Egfr signaling
by: Pei Yu Wang, et al.
Published: (2009)

The development of an antibody affinity enrichment and mass spectrometry-based assay (iMALDI) for the characterization of EGFR and EGFR isoforms from human brain cancer tissue
by: Shah, Brinda
Published: (2011)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
by: Anbang Wang, et al.
Published: (2020-01-01)

EGFR-TKIs resistance via EGFR-independent signaling pathways
by: Qian Liu, et al.
Published: (2018-02-01)

Effect of EGFR-TKI on Lymphangiogenesis of Lung Cancer with EGFR Mutation
by: Minghui CAI, et al.
Published: (2014-12-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
by: Hongjing Zang, et al.
Published: (2020-04-01)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
by: Wang Fen, et al.
Published: (2012-08-01)

Characterisation and regulation of the Egfr/Egfr ligand system in fish models for melanoma
by: Laisney, Juliette Agnès Geneviève Claire
Published: (2010)

Distinguish EGFR+ and EGFR- Patients in Lung adenocarcinoma using CT Images
by: Ting-Wei Weng, et al.
Published: (2017)

Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
by: Shang-Gin Wu, et al.
Published: (2011-01-01)

EGFR is not amplified in ameloblastoma
by: Abreu Alves, F., et al.
Published: (2018)

EGFR and SOX2 crosstalk determines EGFR-TKI sensitivity and tumor progression
by: LEE, AN-CHUN, et al.
Published: (2018)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
by: Beth O. Van Emburgh, et al.
Published: (2016-12-01)

THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY
by: Balko, Justin M.
Published: (2009)

The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
by: Xiaofei Chang, et al.
Published: (2013-01-01)

An investigation of EGFR binding and modulation of EGFR signalling pathways using synthetic peptides
by: Hamilton, S. J.
Published: (2004)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
by: Takahiro Yoshizawa, et al.
Published: (2021-04-01)

Haploinsufficiency of Tumor Suppressor Genes is Driven by the Cumulative Effect of microRNAs, microRNA Binding Site Polymorphisms and microRNA Polymorphisms: An in silico Approach
by: Mayakannan Manikandan, et al.
Published: (2012-01-01)

Haploinsufficiency of Tumor Suppressor Genes is Driven by the Cumulative Effect of microRNAs, microRNA Binding Site Polymorphisms and microRNA Polymorphisms: An In silico Approach
by: Mayakannan Manikandan, et al.
Published: (2012-08-01)

Mining the 3′UTR of Autism-implicated Genes for SNPs Perturbing MicroRNA Regulation
by: Varadharajan Vaishnavi, et al.
Published: (2014-04-01)

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
by: Rintu Thomas, et al.
Published: (2019-05-01)

EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis
by: Ali-Osman Francis, et al.
Published: (2011-03-01)

High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms
by: Radhika Thokala, et al.
Published: (2021-09-01)

RENCA macrobeads inhibit tumor cell growth via EGFR activation and regulation of MEF2 isoform expression
by: Martis, Prithy Caroline
Published: (2020)

Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis
by: Xishan Chen, et al.
Published: (2021-08-01)

KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma
by: Xu H, et al.
Published: (2020-08-01)

A Chimeric Egfr Protein Reporter Mouse Reveals Egfr Localization and Trafficking In Vivo
by: Yu-Ping Yang, et al.
Published: (2017-05-01)

Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer
by: Milica Momcilovic, et al.
Published: (2017-01-01)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
by: Chengjuan Zhang, et al.
Published: (2017-01-01)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
by: Fu-Tsai Chung, et al.
Published: (2015-01-01)

Characterization of the Small Compounds -T315 on EGFR Degradation in EGFR-TKI Resistant Lung Adenocarcinoma
by: Kuo-Yen Huang, et al.
Published: (2015)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
by: Liang Shi, et al.
Published: (2021-03-01)

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
by: Xiaojing Du, et al.
Published: (2021-05-01)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
by: Cheng WC, et al.
Published: (2021-01-01)

Emerging functions of the EGFR in cancer
by: Sara Sigismund, et al.
Published: (2018-01-01)

Role of EGFR in the Nervous System
by: Roberta Romano, et al.
Published: (2020-08-01)